Cutting-edge studies reveal new molecular insights improving cancer treatment strategies. GSK scientists presented data on GSK-5862611, an anti-Sortilin antibody, restoring critical protein function in ALS models. Research on cancer-associated fibroblasts (CAFs) highlights their paradoxical role in promoting tumor progression and drug resistance, emphasizing the need for targeted therapies. Novel PD-L1xVEGF bispecific antibodies from ImmuneOnco and Instil Bio showed early promise in shrinking lung tumors. Furthermore, B cell-driven immunometabolic interventions suppress liver cancer progression by reprogramming the tumor microenvironment, as documented in Nature. These findings refine understanding of tumor biology and open avenues for innovative immunotherapies.